drugset / Trial / NCT01843049

Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer

NCT01843049

Phase 1/2 Unknown 40 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

Most local failures after definitive chemoradiation for unresectable esophageal cancer occur in the gross tumor volume (GTV). And the metabolic active areas post-treatment were located in the high FDG uptake areas prior to the radiotherapy. The hypothesis is that selective dose boost to the esophageal GTV could be safely delivered using a simultaneous integrated boost (SIB) technique, and that boosting the high 18F-deoxyglucose (FDG) uptake areas of the esophageal GTV defined prior to treatment may improve local tumor control.

Timeline

Start
2013-01
Primary completion
2015-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 25 mg/m2 Intravenous
Subject fluorouracil Small molecule 500 mg/m2 Intravenous
Subject fluorouracil Small molecule 600 mg/m2 Intravenous

Indications